IgG4 related disease (a proliferative, fibrotic dz) manifestations by Dr Aisha Dua at RWCS @anisha_dua #rwcs23 @RWCSmtg @RheumNow https://t.co/hy6ZuOY2Ti

New Laboratory Insights for the ANA+ Consult A new study suggests that use of ELISA assays for CXCL-10 and IFN-α can predict which ANA+ individuals may progress to developing a systemic autoimmune rheumatic disease (SARD). https://t.co/Ub9pUHPRrV https://t.co/5q2yrNLD5e

While his talk didn’t focus on treatment, thoughtfulness regarding treatment for pain is important to our patients. Dr. Mease @RWCSmtg @RheumNow #RWCS23 https://t.co/f946SSeRWo

Dr. Shenoi discusses a new bio markers in sJIA lung disease. #RWCS23 ⁦@RheumNow⁩ ⁦@RWCSmtg⁩ https://t.co/Nn3KjmGNfu

How do you treat sJIA lung disease? Lots of steroids. Lung disease may stabilize but may not resolve. Dr. Shenoi ⁦@RWCSmtg⁩ #RWCS23 ⁦@RheumNow⁩ https://t.co/d5HiRy4Ud4

MIS-c 2023 updated diagnostic criteria broken down by information type. Dr. Shenoi #RWCS23 @RheumNow @RWCSmtg https://t.co/U24sQiEF37

Have you heard of nipocalimab? It prevents IgG-FcRn by binding to the FcRn IgG binding site. This is one to watch in our diseases (RA, Sjogren’s, SLE, myopathies.) Dr. Postolova #RWCS23 ⁦@RheumNow⁩ ⁦@RWCSmtg⁩ https://t.co/qMGA6IdtUE

Sex differences in neutrophils could be an interesting approach to consider with our diseases. I personally had no idea my neutrophils may be different than a males. A very interesting thought by Dr. Postolova @RWCSmtg #RWCS23 @RheumNow https://t.co/mZsFaCBk7f

“Remote patient monitoring should be here to stay.” Here are some important codes needed for your clinical practice. #RWCS23 ⁦@RheumNow⁩ ⁦@RWCSmtg⁩ ⁦@alvinwellsmd⁩ https://t.co/dj1CpU7ChY

Drug Safety Differences w/ New Therapies in RA Safety outcomes for targeted synthetic or b/ts DMARDs used to treat RA were studied using data from the ARTIS registry. https://t.co/U96LiasMhW https://t.co/f2oCHs04Q3

Comparison of MIS-C dz in kids and adults>21 (MISC - A). By Dr Susan Shenoi @RWCSmtg #rwcs23 https://t.co/jvsMLARkCA